Precision BioSciences, Inc. (NASDAQ:DTIL) Receives Consensus Rating of “Moderate Buy” from Analysts

Posted by George Bondi on Aug 23rd, 2026

Precision BioSciences, Inc. (NASDAQ:DTIL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $32.25.

A number of analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reissued a “buy” rating on shares of Precision BioSciences in a research note on Monday, August 3rd. Oppenheimer initiated coverage on shares of Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precision BioSciences in a report on Wednesday, August 5th.

Read Our Latest Report on DTIL

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new stake in shares of Precision BioSciences in the 2nd quarter valued at approximately $467,000. Bank of America Corp DE lifted its stake in Precision BioSciences by 167.6% in the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock valued at $151,000 after purchasing an additional 17,172 shares during the last quarter. Quantinno Capital Management LP acquired a new stake in Precision BioSciences in the first quarter valued at approximately $104,000. Octagon Capital Advisors LP grew its stake in shares of Precision BioSciences by 16.6% during the first quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock worth $12,302,000 after buying an additional 318,737 shares during the last quarter. Finally, Affinity Asset Advisors LLC acquired a new position in shares of Precision BioSciences during the first quarter worth $3,289,000. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Stock Up 1.5%

DTIL stock opened at $8.85 on Friday. The company has a market cap of $244.26 million, a PE ratio of -3.16 and a beta of 1.27. The business has a 50-day simple moving average of $7.64 and a 200 day simple moving average of $6.60. Precision BioSciences has a 52 week low of $3.53 and a 52 week high of $9.62. The company has a quick ratio of 12.82, a current ratio of 12.82 and a debt-to-equity ratio of 0.50.

Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative return on equity of 72.52% and a negative net margin of 96.73%. Sell-side analysts anticipate that Precision BioSciences will post -3.33 EPS for the current fiscal year.

Precision BioSciences Company Profile

(Get Free Report)

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.